CD19-NEGATIVE RELAPSE AFTER CAR-T
INDIA TO CHINA ESCALATION
When CD19 antigen escape causes relapse after NexCAR19, standard options in India are limited. China offers dual-target CD19+CD22 CAR-T trials that address this specific failure mechanism.
analyticsAt a Glance
- check_circle20โ30% of ALL patients who relapse after CD19 CAR-T have CD19-negative disease
- check_circleFlow cytometry on relapse biopsy is essential to confirm CD19 loss
- check_circleCD22 and dual CD19+CD22 CAR-T not commercially available in India
- check_circlePUTH Beijing and SYSUCC Guangzhou run dual-target trials for international patients
What Is CD19-Negative Relapse (Antigen Escape)?
Antigen escape is a mechanism by which cancer cells evade CAR-T therapy by downregulating or losing the target antigen โ in this case CD19 โ rendering CAR-T cells unable to recognise and kill the tumour.
The Escape Mechanism
CD19 CAR-T cells kill all cells expressing CD19. Under this selective pressure, a small pre-existing subpopulation of CD19-negative leukaemia cells survives and expands โ effectively hiding from the CAR-T product.
Incidence
CD19-negative relapse accounts for 20โ30% of ALL relapses after CD19 CAR-T therapy, based on published series from ZUMA and ELIANA trials. With NexCAR19, comprehensive data are emerging as follow-up accumulates.
Detection by Flow Cytometry
At relapse, a bone marrow biopsy with detailed flow cytometry panel including CD19, CD22, CD34, and lineage markers is essential. Loss of CD19 expression on blasts confirms antigen escape. This is the critical diagnostic step that determines the next treatment pathway.
Partial vs Complete Loss
Some relapses show dim or partial CD19 expression โ a borderline state where a second CD19 CAR-T may still have marginal activity. Others show complete CD19 negativity. The exact staining intensity guides therapy selection.
India-to-China Escalation: CancerFax Process
CancerFax has a structured pathway for patients who relapse CD19-negatively after NexCAR19 and require dual-target CAR-T access in China.
- 1
Confirm CD19-Negative Status
Submit bone marrow biopsy and flow cytometry report to CancerFax. We verify CD19 negativity and confirm that CD22 expression is present โ a prerequisite for CD22 or dual CAR-T eligibility.
- 2
Case Eligibility Review
CancerFax reviews full treatment history: prior lines, NexCAR19 infusion date, response depth, current disease burden, ECOG status, organ function, and any bridging therapy status.
- 3
Chinese Centre Matching
Based on disease characteristics and trial availability, CancerFax contacts PUTH Beijing or SYSUCC Guangzhou haematology teams for dual-target trial eligibility pre-screening.
- 4
Documentation Preparation
CancerFax compiles required Chinese-centre documentation: structured English medical summary, translated flow cytometry, FISH/cytogenetics, NGS if available, and ECG + organ function.
- 5
Visa and Travel
Chinese M visa application with hospital invitation letter. Interpreter coordination. Flight and accommodation guidance for Beijing or Guangzhou. Arrival-to-consultation timeline is typically 15โ20 days from first contact.
CD19-Negative Relapse: Key Numbers
- 20โ30%CD19-Negative Relapse Rate After CD19 CAR-T in ALLApproximately 1 in 4 patients who relapse after CD19 CAR-T will have CD19-negative disease.
- CD22+Alternative Target โ Present in Most ALL RelapsesCD22 remains expressed on the majority of ALL cells even after CD19 loss, making it the primary alternative CAR-T target.
- 2Active Chinese Centres with Dual-Target Trials (via CancerFax)PUTH Beijing and SYSUCC Guangzhou both run enrolling dual CD19+CD22 CAR-T trials accessible to international patients.
- 15โ20 daysTypical Time from CancerFax Contact to China ArrivalFor patients with complete documentation and M visa approval โ the standard escalation timeline.
What Chinese Centres Require for Dual-Target Trial
Chinese CAR-T centres have specific documentation and eligibility requirements for international patients. CancerFax prepares all materials in the required format.
Clinical Documentation
Bone marrow biopsy report confirming CD19-negative relapse; flow cytometry with full immunophenotype panel; prior treatment summary including NexCAR19 infusion date and response; cytogenetics (karyotype and FISH for del9p, IGH rearrangements).
Molecular Data
NGS report (if available) identifying any FLT3, IDH1/2, or TP53 mutations relevant to prognosis; MRD status by PCR or NGS if assessed; prior minimal residual disease data.
Organ Function
Current CBC with differential, comprehensive metabolic panel (creatinine, ALT, bilirubin), cardiac echo with LVEF โฅ 50%, ECOG performance status assessment by treating physician.
Bridging Therapy Status
Chinese centres prefer patients to have manageable disease burden โ not active blast crisis. A brief bridging regimen may be required before leukapheresis in China. CancerFax advises on whether bridging in the home country before travel is advisable.
More from the CAR-T Resource Library
Explore related guides on India's CAR-T programme, China escalation, and dual-target options.
Frequently Asked Questions โ CD19-Negative Relapse
How do I know if my relapse is CD19-negative?
CD19 status at relapse is determined by flow cytometry on a fresh bone marrow aspirate. The CD19 channel will show absent or markedly diminished expression compared to the original diagnostic sample. This test is routinely available at any major Indian haematology centre. If your relapse biopsy has not been tested for CD19 by flow cytometry, request this urgently โ it changes the entire treatment pathway.
Can I get a second CD19 CAR-T if I relapse CD19-positive?
If relapse is CD19-positive (antigen retained), a second CD19 CAR-T may have limited efficacy due to prior CAR-T cell exhaustion and anti-vector immune responses. Some patients do respond to a second infusion, particularly with different CAR-T constructs. Your haematologist should assess CAR-T persistence data and feasibility. CD19-positive relapse with partial response may also be eligible for certain Chinese trial protocols โ CancerFax can review this.
Does blinatumomab work for CD19-negative relapse?
No. Blinatumomab (blincyto) is a bispecific T-cell engager that also targets CD19. It will have no mechanism of action against CD19-negative blasts. If CD19 loss is confirmed, blinatumomab should not be used as salvage โ this is a common and important clinical mistake to avoid.
How long does the India-to-China CAR-T process take?
From first contact with CancerFax to arriving at a Chinese centre, the typical timeline is 15โ20 days for patients with complete documentation. Chinese M visa processing is 5โ10 business days. Leukapheresis at the Chinese centre occurs within days of arrival for approved patients. Manufacturing takes 3โ4 weeks, followed by lymphodepletion and infusion. Total time from first contact to infusion is approximately 8โ10 weeks.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Suspected CD19-Negative Relapse After CAR-T?
CancerFax reviews your post-CAR-T relapse biopsy and flow cytometry, and helps identify whether dual-target trials in China are appropriate for your case.
This content is for informational purposes only and does not constitute medical advice. Relapse evaluation must be managed by your treating haematologist.